54 articles for M Zhou
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.
Roche Innovation Center Shanghai
Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.
China Pharmaceutical University
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Hoffmann-La Roche
Self-organizing molecular field analysis on humanß-secretase nonpeptide inhibitors: 5, 5-disubstituted aminohydantoins.
Sichuan University
Studies on two types of PTP1B inhibitors for the treatment of type 2 diabetes: Hologram QSAR for OBA and BBB analogues.
Tsinghua University
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Roche R & D Center China
Cortisone dissociates the Shaker family K+ channels from their beta subunits.
Columbia University College of Physicians and Surgeons
The U.S. FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective.
Sichuan University
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers.
Kronos Bio
Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection.
China Innovation Center of Roche
Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities.
Bristol Myers Squibb
Identification of a Novel Potent CYP4Z1 Inhibitor Attenuating the Stemness of Breast Cancer Cells through Lead Optimization.
China Pharmaceutical University
Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease.
Baylor University
Discovery and computational studies of 2-phenyl-benzoxazole acetamide derivatives as promising P2Y
Soochow University
Sortase A-mediated cyclization of novel polycyclic RGD peptides for α
Hefei Normal University
Discovery of Cyclic Peptidomimetic Ligands Targeting the Extracellular Domain of EGFR.
University of South Florida
Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
Guizhou Medical University
Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
Anhui University of Chinese Medicine
Discovery of a PROTAC targeting ALK with in vivo activity.
West China Hospital of Sichuan University
Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design.
West China Hospital of Sichuan University
Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
Southern Medical University
Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
Zhejiang Hisun Pharmaceutical
Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.
TBA
Development of novel NLRP3-XOD dual inhibitors for the treatment of gout.
Soochow University
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
Roche Innovation Center Shanghai
Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of
East China Normal University and Shanghai Fengxian District Central Hospital Joint Center For Translational Medicine
Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Nankai University
Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.
West China Hospital of Sichuan University
Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor.
Roche Pharma Research and Early Development
Design, synthesis and anti-inflammatory evaluation of 3-amide benzoic acid derivatives as novel P2Y
China Pharmaceutical University
Cytotoxic Components from Hypericum elodeoides Targeting RXRα and Inducing HeLa Cell Apoptosis through Caspase-8 Activation and PARP Cleavage.
Xiamen University
Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
Central South University
Molecular docking and 3D-QSAR on 2-(oxalylamino) benzoic acid and its analogues as protein tyrosine phosphatase 1B inhibitors.
Graduate University of Chinese Academy of Sciences
Design, synthesis and biological evaluation of novel xanthine oxidase inhibitors bearing a 2-arylbenzo[b]furan scaffold.
China Pharmaceutical University
Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout.
Soochow University
High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
Nanjing Forestry University
Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode.
Bristol-Myers Squibb
Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.
Bristol-Myers Squibb
Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
Hoffmann-La Roche
Pyridopyrimidine derivative, preparation method therefor and medical use thereof
Jiangsu Hengrui Medicine Co.
Polycyclic carbamoylpyridone derivatives, pharmaceutical compositions and use thereof
Jiaxing Andicon Biotech Co.
NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF
Shanghai Longwood Biopharmaceuticals
Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.
Universita Di Siena